Immediate Impact
51 standout
Citing Papers
Recent advances in self-targeting natural product-based nanomedicines
2025 Standout
Cystic fibrosis
2024 Standout
Works of Peter J. Barry being referenced
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
2019
WS01.4 GLPG2222 in subjects with cystic fibrosis and the F508del/Class III mutation on stable treatment with ivacaftor: results from a phase II study (ALBATROSS)
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Peter J. Barry | 52 | 3 | 53 | 42 | 10 | 171 | |
| David M. Weinreich | 66 | 1 | 84 | 62 | 9 | 218 | |
| Pooja Khamar | 9 | 2 | 80 | 94 | 17 | 284 | |
| Alice T. Gasch | 11 | 6 | 187 | 73 | 10 | 266 | |
| Rachel Varughese | 21 | 1 | 41 | 37 | 10 | 123 | |
| Marco Schiuma | 22 | 1 | 179 | 103 | 15 | 288 | |
| Eugene Protzko | 13 | 2 | 191 | 24 | 12 | 259 | |
| Chiao‐Chin Lee | 23 | 2 | 18 | 7 | 12 | 169 | |
| Sachin Mehta | 8 | 1 | 51 | 33 | 16 | 201 | |
| Domenica Zaino | 24 | 1 | 9 | 15 | 9 | 207 | |
| Christopher Seamone | 5 | 2 | 64 | 60 | 12 | 201 |
All Works
Loading papers...